Response Surface Methodology: An Extensive Potential to Optimize in vivo Photodynamic Therapy Conditions

International Journal of Radiation Oncology Biology Physics

Volumn 75, Issue 1, 2009, Pages 244-252

  Tirand, Loraine ^a   Bastogne, Thierry ^a,c   Bechet, Denise ^a   Linder, Michel ^b   Thomas, Noémie ^a   Frochot, Céline ^b,c   Guillemin, François ^a,c   Barberi Heyob, Muriel ^a,c  

^a CENTRE DE RECHERCHE EN AUTOMATIQUE DE NANCY   (France)

^b UNIVERSITÉ DE LORRAINE   (France)

^c GDR 3049 Médicaments Photoactivables Photochimiothérapie PHOTOMED   (France)

Author keywords

Doehlert experimental design; Dosimetry; In vivo; Photodynamic therapy; Response surface methodology

Indexed keywords

DESIGNED EXPERIMENTS; DIAMETER GROWTH; DOEHLERT; DOEHLERT EXPERIMENTAL DESIGN; DRUG-LIGHT INTERVALS; EMPIRICAL MODELING; EXPERIMENTAL APPROACHES; EXPERIMENTAL CONDITIONS; EXPERIMENTAL DESIGN; FLUENCE RATES; FLUENCES; IN VIVO; MALIGNANT GLIOMA; NONCONJUGATED; NUDE MICE; OPTIMAL VALUES; RAPID TESTING; RATIONAL SOLUTION; RESPONSE SURFACE METHODOLOGY; TREATMENT CONDITIONS; TUMOR GROWTH; TUMOR VOLUMES;

AMINES; ANIMALS; CELL MEMBRANES; DOSIMETERS; DOSIMETRY; DRUG INTERACTIONS; GROWTH (MATERIALS); LIGHT TRANSMISSION; MATLAB; OPTICAL MATERIALS; OPTIMIZATION; OXYGEN; PEPTIDES; PLASMONS; STATISTICS; SURFACE PROPERTIES; SURFACE TESTING; TUMORS;

PHOTODYNAMIC THERAPY;

NEUROPILIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RADIATION DOSE; RESPONSE SURFACE METHOD; TUMOR GROWTH; TUMOR VOLUME; XENOGRAFT;

ALGORITHMS; ANIMALS; CELL LINE, TUMOR; FEMALE; GLIOMA; HUMANS; MICE; MICE, NUDE; MODELS, STATISTICAL; NEUROPILIN-1; OLIGOPEPTIDES; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; TIME FACTORS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 68949104338     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.04.004     Document Type: Article

References (28)

1. Brown S.B., Brown E.A., and Walker I. The present and future role of photodynamic therapy in cancer treatment. Lancet Oncol 5 (2004) 497-508
2. Tirand L., Frochot C., Vanderesse R., et al. A peptide competing with VEGF165 binding on neuropilin-1 mediates targeting of a chlorin-type photosensitizer and potentiates its photodynamic activity in human endothelial cells. J Control Release 111 (2006) 153-164
3. Jarvi M.T., Niedre M.J., Patterson M.S., et al. Singlet oxygen luminescence dosimetry (SOLD) for photodynamic therapy: current status, challenges and future prospects. Photochem Photobiol 82 (2006) 1198-1210
4. Wilson B.C., Patterson M.S., and Lilge L. Implicit and explicit dosimetry in photodynamic therapy: A new paradigm. Lasers Med Sci 12 (1997) 182-199
5. Hetzel F.W., Brahmavar S.M., Chen Q., et al. Photodynamic therapy dosimetry. A Task Group Report of the General Medical Physics Committee of the Science Council. Med Phys 88 (2005) 1-30
6. Zhou X., Chen B., Hoopes P.J., et al. Tumor vascular area correlates with photosensitizer uptake: Analysis of verteporfin microvascular delivery in the Dunning rat prostate tumor. Photochem Photobiol 82 (2006) 1348-1357
7. Wood S.R., Holroyd J.A., and Brown S.B. The subcellular localization of Zn(II) phthalocyanines and their redistribution on exposure to light. Photochem Photobiol 65 (1997) 397-402
8. Wilson B.C., and Patterson M.S. The physics, biophysics and technology of photodynamic therapy. Phys Med Biol 53 (2008) 61-109
9. Robinson D.J., de Bruijn H.S., van der Veen N., et al. Fluorescence photobleaching of ALA-induced protoporphyrin IX during photodynamic therapy of normal hairless mouse skin: the effect of light dose and irradiance and the resulting biological effect. Photochem Photobiol 67 (1998) 140-149
10. Chen Q., Wilson B.C., Shetty S.D., et al. Changes in in vivo optical properties and light distributions in normal canine prostate during photodynamic therapy. Radiat Res 147 (1997) 86-91
11. Niedre M.J., Patterson M.S., Giles A., et al. Imaging of photodynamically generated singlet oxygen luminescence. in vivo. Photochem Photobiol 81 (2005) 941-943
12. Jones H.J., Vernon D.I., and Brown S.B. Photodynamic therapy effect of m-THPC (Foscan) in vivo: Correlation with pharmacokinetics. Br J Cancer 89 (2003) 398-404
13. Thomas N., Tirand L., Chatelut E., et al. Tissue distribution and pharmacokinetics of an ATWLPPR-conjugated chlorin-type photosensitizer targeting neuropilin-1 in glioma-bearing nude mice. Photochem Photobiol Sci 7 (2008) 433-441
14. Tirand L., Thomas N., Dodeller M., et al. Metabolic profile of a peptide-conjugated chlorin-type photosensitizer targeting neuropilin-1: an in vivo and in vitro study. Drug Metab Dispos 35 (2007) 806-813
15. Cramers P., Ruevekamp M., Oppelaar H., et al. Foscan uptake and tissue distribution in relation to photodynamic efficacy. Br J Cancer 88 (2003) 283-290
16. Box GEP, Wilson KB, eds. On the experimental attainment of optimum conditions. 1951.
17. Box GEP, Draper NR, eds. Empirical model-building and response surfaces. 1987.
18. Carter Jr. W., and Wampler G. Review of the application of response surface methodology in the combination therapy of cancer. Cancer Treat Rep 70 (1986) 133-140
19. Pinel S., Barberi-Heyob M., Cohen-Jonathan E., et al. Erythropoietin-induced reduction of hypoxia before and during fractionated irradiation contributes to improvement of radioresponse in human glioma xenografts. Int J Radiat Oncol Biol Phys 59 (2004) 250-259
20. Triesscheijn M., Baas P., Schellens J.H., et al. Photodynamic therapy in oncology. Oncologist 11 (2006) 1034-1044
21. Galle J., Loeffler M., and Drasdo D. Modeling the effect of deregulated proliferation and apoptosis on the growth dynamics of epithelial cell populations in vitro. Biophys J 88 (2005) 62-75
22. Gill K.R., Wolfsen H.C., Preyer N.W., et al. Pilot study on light dosimetry variables for photodynamic therapy of Barrett's esophagus with high-grade dysplasia. Clin Cancer Res 15 (2009) 1830-1836
23. Bechet D., Couleaud P., Frochot C., et al. Nanoparticles as vehicles for delivery of photodynamic therapy agents. Trends Biotechnol 26 (2009) 612-621
24. Schneider R., Tirand L., Frochot C., et al. Recent improvements in the use of synthetic peptides for a selective photodynamic therapy. Anticancer Agents Med Chem 6 (2006) 469-488
25. Taquet J.P., Frochot C., Manneville V., et al. Phthalocyanines covalently bound to biomolecules for a targeted photodynamic therapy. Curr Med Chem 14 (2007) 1673-1687
26. Pogue B.W., O'Hara J.A., Demidenko E., et al. Photodynamic therapy with verteporfin in the radiation-induced fibrosarcoma-1 tumor causes enhanced radiation sensitivity. Cancer Res 63 (2003) 1025-1033
27. Zhou X., Pogue B.W., Chen B., et al. Pretreatment photosensitizer dosimetry reduces variation in tumor response. Int J Radiat Oncol Biol Phys 64 (2006) 1211-1220
28. Henderson B.W., Busch T.M., Vaughan L.A., et al. Photofrin photodynamic therapy can significantly deplete or preserve oxygenation in human basal cell carcinomas during treatment, depending on fluence rate. Cancer Res 60 (2000) 525-529